Mercado de medicamentos inyectables liofilizados de Oriente Medio y África, por envase (viales, jeringas de doble cámara, cartuchos de doble cámara y otros), clase de medicamento (antiinfeccioso, antineoplásico, diuréticos, inhibidor de la bomba de protones, anestésico, anticoagulante, AINE, corticosteroides y otros), forma (polvo y líquido), indicación (oncología, enfermedades autoinmunes, trastornos hormonales, enfermedades respiratorias, trastornos gastrointestinales, trastornos dermatológicos, enfermedades oftálmicas y otros), vía de administración (intravenosa/infusión, intramuscular y otros), usuario final (hospital, clínicas, atención médica domiciliaria y otros), canal de distribución (licitación directa, ventas minoristas y otros), país (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto y resto de Oriente Medio y África), tendencias de la industria y pronóstico hasta 2028.
Análisis y perspectivas del mercado: mercado de medicamentos inyectables liofilizados en Oriente Medio y África
Se espera que el mercado de medicamentos inyectables liofilizados gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 4,2% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 208,14 millones para 2028. Se espera que el aumento de las condiciones de salud crónicas en todo el mundo actúe como un motor para impulsar la demanda del mercado de medicamentos inyectables liofilizados.
La liofilización es otro término para denominar a la liofilización. Se trata de una técnica que consiste en aislar un material sólido de un disolvente mediante la congelación y evaporación de la solución al vacío. Se considera que los productos liofilizados tienen una vida útil más larga que los medicamentos convencionales y, por lo tanto, son los más adecuados. La protección de productos biológicos, proteínas, anticuerpos, microorganismos, parenterales, plasma sanguíneo, enzimas, reactivos de diagnóstico, vacunas y nutracéuticos se realiza habitualmente mediante liofilización. Para mantener estables algunos ingredientes a granel inestables, es necesaria la liofilización del inyectable estéril.
Se espera que el creciente avance tecnológico de los medicamentos inyectables liofilizados actúe como un impulsor para impulsar la demanda del mercado de medicamentos inyectables liofilizados. Se espera que el aumento en el número de retiradas de productos de medicamentos liofilizados y el tipo de envase actúen como restricción del mercado de medicamentos inyectables liofilizados. Se espera que el aumento en las aprobaciones regulatorias para medicamentos liofilizados actúe como una oportunidad para impulsar la demanda del mercado de medicamentos inyectables liofilizados. Se espera que los factores asociados con la fabricación de viales liofilizados para productos parenterales desafíen la demanda del mercado de medicamentos inyectables liofilizados.
El informe de mercado de medicamentos inyectables liofilizados proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de medicamentos inyectables liofilizados, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de medicamentos inyectables liofilizados
El mercado de medicamentos inyectables liofilizados se clasifica en siete segmentos notables que se basan en el envase, la clase de medicamento, la forma, la indicación, la vía de administración, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- En función del envasado, el mercado de medicamentos inyectables liofilizados se segmenta en viales, jeringas de doble cámara, cartuchos de doble cámara y otros. En 2021, se espera que el segmento de viales domine el mercado de medicamentos inyectables liofilizados porque la mayoría de los medicamentos inyectables liofilizados se envasan en viales, por lo que es influyente y está creciendo en el mercado.
- Según la clase de fármaco, el mercado de fármacos inyectables liofilizados se segmenta en antiinfecciosos, antineoplásicos, diuréticos, inhibidores de la bomba de protones, anestésicos, anticoagulantes, AINE, corticosteroides y otros. En 2021, se espera que el segmento de antiinfecciosos domine el mercado de fármacos inyectables liofilizados debido a la mayor demanda de antibióticos y fármacos antivirales en todo el mundo.
- En función de la forma, el mercado de medicamentos inyectables liofilizados se segmenta en polvo y líquido. En 2021, se espera que el segmento de polvo domine el mercado de medicamentos inyectables liofilizados debido a su fácil y seguro almacenamiento y transporte en todo el mundo.
- Según las indicaciones, el mercado de medicamentos inyectables liofilizados se segmenta en oncología, enfermedades autoinmunes, trastornos hormonales, enfermedades respiratorias, trastornos gastrointestinales, trastornos dermatológicos, enfermedades oftálmicas y otros. En 2021, se espera que el segmento de oncología domine el mercado de medicamentos inyectables liofilizados debido a la disponibilidad de un mayor número de medicamentos inyectables liofilizados para oncología.
- Según la vía de administración, el mercado de medicamentos inyectables liofilizados se segmenta en intravenoso/infusión, intramuscular y otros. En 2021, se espera que el segmento intravenoso/infusión domine el mercado de medicamentos inyectables liofilizados debido a la biodisponibilidad del 100 % del medicamento a través de esta vía de administración.
- On the basis of end user, the lyophilized injectable drugs market is segmented into hospital, clinics, home healthcare and others. In 2021, hospital segment is expected to dominate the lyophilized injectable drugs market due to the financial capabilities of hospitals to purchase luxurious equipment along with the presence of trained professionals to administer them.
- On the basis of distribution channel, the lyophilized injectable drugs market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the lyophilized injectable drugs market because most of the service providers buy the lyophilized injectable drugs from manufacturers and it is noticed that revenue from direct sales is higher, so it is influential as well as growing in the market.
Middle East and Africa Lyophilized Injectable Drugs Market Country Level Analysis
Middle East and Africa lyophilized injectable drugs market is analysed and market size information is provided by the country, packaging, drug class, form, indication, route of administration, end user and distribution channel as referenced above.
The countries covered in the Middle East and Africa lyophilized injectable drugs market are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa.
Saudi Arabia is expected to dominate in the Middle East and Africa lyophilized injectable drugs market due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
New Product Launches by Manufacturers is creating new opportunities for Players in the Lyophilized Injectable Drugs Market
The lyophilized injectable drugs market also provides you with detailed market analysis for every country growth in lyophilized injectable drugs industry with lyophilized injectable drugs market sales, impact of advancement in the lyophilized injectable drugs market and changes in regulatory scenarios with their support for the lyophilized injectable drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lyophilized Injectable Drugs Market Share Analysis
El panorama competitivo del mercado de medicamentos inyectables liofilizados proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de medicamentos inyectables liofilizados de Oriente Medio y África.
Las principales empresas cubiertas en el informe del mercado de medicamentos inyectables liofilizados de Oriente Medio y África son Genex Pharma, Aristopharma Ltd., Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Inc., Zydus Cadila, Cipla Inc., Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Sanofi, Celon Laboratories Pvt. Ltd. y Baxter, entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de medicamentos inyectables liofilizados.
- En noviembre de 2019, Pfizer, Inc. anunció que su división, denominada Upjohn, se fusionaría con Mylan NV y formaría una nueva empresa llamada Viatris Inc. Esta combinación de la división comercial de la empresa con Mylan NV ha aumentado su cartera de productos, lo que ha provocado una mayor demanda de su producto en el mercado.
La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de medicamentos inyectables liofilizados, lo que también proporciona el beneficio para que la organización mejore su oferta para el mercado de medicamentos inyectables liofilizados.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGING LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN CHRONIC HEALTH CONDITIONS
6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE
6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES
6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS
6.1.5 TECHNOLOGICAL ADVANCEMENTS
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLESTICK INJURIES
6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE
6.3 OPPORTUNITIES
6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS
6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS
6.3.3 QUALITY CONCERNS
6.4 CHALLENGES
6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS
6.4.2 TIME-CONSUMING PROCESS AND HIGH COST
7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT IN DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVE
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING
8.1 OVERVIEW
8.2 VIALS
8.3 DUAL-CHAMBER SYRINGES
8.4 DUAL-CHAMBER CARTRIDGES
8.5 OTHERS
9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFECTIVE’S
9.2.1 ANTIBIOTICS
9.2.1.1 Azithromycin
9.2.1.2 Doxycycline
9.2.1.3 Vancomycin
9.2.1.4 Polymyxin B
9.2.1.5 Piperacillin
9.2.1.6 Tazobactam
9.2.1.7 Others
9.2.2 ANTIFUNGAL
9.2.2.1 Mycamine
9.2.2.2 Caspofungin Acetate
9.2.2.3 Isavuconazonium Sulfate
9.2.2.4 Amphotericin
9.2.2.5 Others
9.2.3 ANTIVIRAL
9.2.3.1 Acyclovir
9.2.3.2 Ganciclovir
9.2.3.3 Remdesivir
9.2.3.4 Others
9.2.4 OTHERS
9.3 ANTINEOPLASTIC
9.3.1 METHOTREXATE
9.3.2 GEMCITABINE
9.3.3 CYTARABINE
9.3.4 FLUDARABINE
9.3.5 DOXORUBICIN
9.3.6 OXALIPLATIN
9.3.7 ZOLEDRONIC ACID
9.3.8 OTHERS
9.4 DIURETICS
9.4.1 CHLOROTHIAZIDE
9.4.2 ETHACRYNIC ACID
9.4.3 ACETAZOLAMIDE
9.4.4 OTHERS
9.5 PROTON PUMP INHIBITOR
9.5.1 ESOMEPRAZOLE SODIUM
9.5.2 PANTOPRAZOLE SODIUM
9.5.3 OMEPRAZOLE
9.5.4 OTHERS
9.6 ANESTHETIC
9.6.1 VECURONIUM BROMIDE
9.6.2 SODIUM THIOPENTAL
9.6.3 LIDOCAINE
9.6.4 OTHERS
9.7 ANTICOAGULANT
9.7.1 COUMADIN
9.7.2 UROKINASE
9.7.3 ANTITHROMBIN (RECOMBINANT)
9.7.4 APIXABAN
9.7.5 RIVAROXABAN
9.7.6 OTHERS
9.8 NSAID’S
9.8.1 INDOMETHACIN
9.8.2 IBUPROFEN
9.8.3 DICLOFENAC
9.8.4 KETOROLAC
9.8.5 OTHERS
9.9 CORTICOSTEROIDS
9.9.1 HYDROCORTISONE
9.9.2 METHYLPREDNISOLONE
9.9.3 OTHERS
9.1 OTHERS
10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 AUTOIMMUNE DISEASES
11.4 HORMONAL DISORDERS
11.5 RESPIRATORY DISEASES
11.6 GASTROINTESTINAL DISORDERS
11.7 DERMATOLOGICAL DISORDERS
11.8 OPHTHALMIC DISEASES
11.9 OTHERS
12 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS/INFUSION
12.3 INTRAMUSCULAR
12.4 OTHERS
13 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 KUWAIT
15.1.6 ISRAEL
15.1.7 REST OF MIDDLE EAST & AFRICA
16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 CIPLA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 NOVARTIS AG
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 BAXTER
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ZYDUS CADILA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AFFY PHARMA PVT LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AMNEAL PHARMACEUTICALS LLC
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARISTOPHARMA LTD.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 CELON LABORATORIES PVT.LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 CIRONDRUGS
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 GENEX PHARMA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GILEAD SCIENCES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 OTSUKA AMERICA PHARMACEUTICAL, INC
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SANOFI
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tablas
TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS
TABLE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 9 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 58 MIDDLE EAST & AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 77 SOUTH AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 79 SOUTH AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 80 SOUTH AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 81 SOUTH AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 82 SOUTH AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 96 SAUDI ARABIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 99 SAUDI ARABIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 100 SAUDI ARABIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 101 SAUDI ARABIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 102 SAUDI ARABIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 103 SAUDI ARABIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 104 SAUDI ARABIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 105 SAUDI ARABIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 106 SAUDI ARABIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 107 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 108 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 109 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 111 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 112 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 113 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 114 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 115 U.A.E. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 116 U.A.E. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 117 U.A.E. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 118 U.A.E. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 119 U.A.E. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 120 U.A.E. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 121 U.A.E. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 122 U.A.E. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 123 U.A.E. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 124 U.A.E. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 125 U.A.E. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 126 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 127 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 130 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 131 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 132 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 134 EGYPT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 138 EGYPT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 139 EGYPT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 140 EGYPT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 141 EGYPT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 142 EGYPT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 143 EGYPT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 144 EGYPT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 145 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 146 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 147 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 149 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 153 KUWAIT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 164 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 165 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 166 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 170 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 171 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 172 ISRAEL ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 173 ISRAEL ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 174 ISRAEL ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 175 ISRAEL ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 176 ISRAEL ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 177 ISRAEL DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 178 ISRAEL PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 179 ISRAEL ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 180 ISRAEL ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 181 ISRAEL NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 182 ISRAEL CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 183 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 184 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 185 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 187 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 188 REST OF MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
FIGURE 15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020
FIGURE 16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020
FIGURE 20 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020
FIGURE 24 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020
FIGURE 28 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)
FIGURE 48 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
